{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:41:24Z","timestamp":1786545684650,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1038\/ajg.2012.467","type":"journal-article","created":{"date-parts":[[2013,2,12]],"date-time":"2013-02-12T08:00:47Z","timestamp":1360656047000},"page":"392-400","source":"Crossref","is-referenced-by-count":47,"title":["GI-REASONS: A Novel 6-Month, Prospective, Randomized, Open-Label, Blinded Endpoint (PROBE) Trial"],"prefix":"10.14309","volume":"108","author":[{"given":"Byron","family":"Cryer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee S","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurkirpal","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J","family":"Stillman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela F","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-19-20210210","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1001\/archinte.154.3.311","article-title":"Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors.","volume":"154","author":"Garcia Rodriguez","year":"1994","journal-title":"Arch Intern Med"},{"key":"R2-19-20210210","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1053\/gast.2001.21907","article-title":"Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient.","volume":"120","author":"Laine","year":"2001","journal-title":"Gastroenterology"},{"key":"R3-19-20210210","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0140-6736(07)60234-7","article-title":"Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.","volume":"369","author":"Laine","year":"2007","journal-title":"Lancet"},{"key":"R4-19-20210210","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1001\/archinte.1996.00440130066007","article-title":"Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study.","volume":"156","author":"Singh","year":"1996","journal-title":"Arch Intern Med"},{"key":"R5-19-20210210","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM199906173402407","article-title":"Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.","volume":"340","author":"Wolfe","year":"1999","journal-title":"N Engl J Med"},{"key":"R6-19-20210210","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.","volume":"343","author":"Bombardier","year":"2000","journal-title":"N Engl J Med"},{"key":"R7-19-20210210","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0140-6736(06)69666-9","article-title":"Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.","volume":"368","author":"Cannon","year":"2006","journal-title":"Lancet"},{"key":"R8-19-20210210","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(04)16893-1","article-title":"Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.","volume":"364","author":"Schnitzer","year":"2004","journal-title":"Lancet"},{"key":"R9-19-20210210","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial.","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"R10-19-20210210","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-123-4-199508150-00001","article-title":"Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial.","volume":"123","author":"Silverstein","year":"1995","journal-title":"Ann Intern Med"},{"key":"R11-19-20210210","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.amjmed.2005.09.054","article-title":"Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.","volume":"119","author":"Singh","year":"2006","journal-title":"Am J Med"},{"key":"R12-19-20210210","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/00001648-199701000-00003","article-title":"Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation.","volume":"8","author":"Gutthann","year":"1997","journal-title":"Epidemiology"},{"key":"R13-19-20210210","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/pds.653","article-title":"Drug switching patterns among patients taking non-steroidal anti-inflammatory drugs: a retrospective cohort study of a general practitioners database in the United Kingdom.","volume":"10","author":"Langman","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R15-19-20210210","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/01.ede.0000135174.63482.43","article-title":"A structural approach to selection bias.","volume":"15","author":"Hernan","year":"2004","journal-title":"Epidemiology"},{"key":"R16-19-20210210","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/08037059209077502","article-title":"Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials.","volume":"1","author":"Hansson","year":"1992","journal-title":"Blood Press"},{"key":"R17-19-20210210","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3899\/jrheum.090168","article-title":"A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract.","volume":"37","author":"Chan","year":"2010","journal-title":"J Rheumatol"},{"key":"R18-19-20210210","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0140-6736(10)60673-3","article-title":"Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.","volume":"376","author":"Chan","year":"2010","journal-title":"Lancet"},{"key":"R19-19-20210210","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1136\/gut.2005.080754","article-title":"Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin, and combinations.","volume":"55","author":"Lanas","year":"2006","journal-title":"Gut"},{"key":"R20-19-20210210","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.pain.2004.09.005","article-title":"Development and validation of the Pain Treatment Satisfaction Scale (PTSS): a patient satisfaction questionnaire for use in patients with chronic or acute pain.","volume":"112","author":"Evans","year":"2004","journal-title":"Pain"},{"key":"R21-19-20210210","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/ajg.2009.164","article-title":"Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice.","volume":"104","author":"Lanas","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R25-19-20210210","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1542-3565(04)00619-6","article-title":"Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo.","volume":"3","author":"Goldstein","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R26-19-20210210","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/j.1365-2036.2007.03312.x","article-title":"Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy.","volume":"25","author":"Goldstein","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R27-19-20210210","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.3748\/wjg.v12.i24.3789","article-title":"Interaction or relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in upper gastrointestinal diseases.","volume":"12","author":"Ji","year":"2006","journal-title":"World J Gastroenterol"},{"key":"R28-19-20210210","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ahj.2008.12.014","article-title":"Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis.","volume":"157","author":"Becker","year":"2009","journal-title":"Am Heart J"},{"key":"R29-19-20210210","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/hr.2008.26","article-title":"Cardiovascular clinical trials in Japan and controversies regarding prospective randomized open-label blinded end-point design.","volume":"32","author":"Kohro","year":"2009","journal-title":"Hypertens Res"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg2012467.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2012467","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2012467.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201303000-00019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:45:13Z","timestamp":1786542313000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201303000-00019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2012.467","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717985374.793472612","asserted-by":"object"}]},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}